| bibliographicCitation |
Deng Z, Jin M, Ou C, Jiang W, Zhao J, Liu X, Sun S, Tang H, He B, Cai S, Chen P, Wu P, Liu Y, Kang J, Zhang Y, Huang M, Xu J, Huang K, Li Q, Zhang X, Fu X, Wang C, Shen H, Zhu L, Shi G, Qiu Z, Wen Z, Wei X, Gu W, Wei C, Wang G, Chen P, Xie L, Lin J, Tang Y, Han Z, Chung KF, Zhang Q, Zhong N; C-BIOPRED Consortium. Eligibility of C-BIOPRED severe asthma cohort for type-2 biologic therapies. Chin Med J (Engl). 2023 Jan 20;136(2):230–2. PMID: 36752798; PMCID: PMC10106261. |